Cell and Gene Therapy
.svg){kind=icon}
Why Genomic Integrity Matters in CGT
Cell and Gene Therapy (CGT) is revolutionizing the treatment of previously untreatable diseases, but ensuring genomic integrity remains one of its greatest challenges. Throughout cell culture, reprogramming, editing, and differentiation, cells can acquire chromosomal rearrangements and other instabilities that impact therapeutic safety and efficacy. While tools like NGS, microarrays, FISH, and karyotyping are widely used, each leaves blind spots—particularly for structural variants (SVs) that play a central role in genome stability. Genome editing technologies such as CRISPR add further complexity, as unintended on- and off-target alterations must be accurately assessed to safeguard translational and clinical success.
Where Current Genomic Tools Fall Short
- Low-resolution, limited to mega-base sized events
- Long turnaround time (requires culturing: +7-14 days)
- Labor-intensive workflow requiring specialized experts
- Limited to specific loci or aneuploid detection
- Not applicable for genome-wide analysis
- Restricted to copy-number variants (CNVs)
- Fails to detect balanced rearrangements
- Limited ability to resolve repeat-rich genomic regions
- Targeted sequencing misses CNVs and SVs
- Limited detection of variants in heterogeneous cell populations
- Genome-wide sequencing is expensive and has low sensitivity for CNVs and SVs
Nabsys closes these gaps with comprehensive, genome-wide SV detection in a single assay.
How EGM Fills the Gap
Advantages of the OhmX Platform
Our Products
The state-of-the-art OhmX Platform uses electronic nano-detectors to deliver the highest resolution for whole genome structural variant analysis. You can now perform whole genome analysis of SVs down to 300bp in size—enabling insights into previously undetectable DNA variations.
Learn More
